

TOXIC AND HAZARDOUS SUBSTANCES LITIGATION


MAY 2025

IN THIS ISSUE

Michael Fox and Robert Kum of Duane Morris LLP, analyze IARC's recent re-classification of gasoline as a carcinogen.

An Analysis of IARC's Recent Re-Evaluation of Gasoline: More Questions Than Answers Raised

ABOUT THE AUTHORS



Michael Fox is the managing partner of Duane Morris LLP's San Francisco office and co-chair of the Firm's Products Liability and Toxic Torts Division. He represents energy companies, chemical, equipment, and drug manufacturers, construction companies, and public entities in toxic tort, environmental release, general liability, serious personal injury, and commercial matters. He is the current Vice Chair of Programs for the IADC's Toxic and Hazardous Substances Litigation Committee. He can be reached at MLFox@duanemorris.com.



Robert Kum is a partner at Duane Morris LLP and a nationally recognized trial attorney. He represents various companies in toxic tort, product liability, and catastrophic personal injury cases for clients based in the United States, Canada, and Asia. He is the Vice-Chair of the Products Liability and Toxic Torts Division of the Firm's Trial Practice Group. He can be reached at rkum@duanemorris.com.

ABOUT THE COMMITTEE

Member participation is the focus and objective of the Toxic and Hazardous Substances Litigation Committee, whether through a monthly newsletter, committee Community page, e-mail inquiries and contacts regarding tactics, experts and the business of the committee, semi-annual committee meetings to discuss issues and business, Journal articles and other scholarship, our outreach program to welcome new members and members waiting to get involved, or networking and CLE presentations significant to the experienced trial lawyer defending toxic tort and related cases. Learn more about the Committee at www.iadclaw.org. To contribute a newsletter article, contact:



Joel Eagle
Committee Chair
Thompson Hine LLP
Joel.Eagle@ThompsonHine.com

The International Association of Defense Counsel serves a distinguished, invitation-only membership of corporate and insurance defense lawyers. The IADC dedicates itself to enhancing the development of skills, professionalism and camaraderie in the practice of law in order to serve and benefit the civil justice system, the legal profession, society and our members.

On January 12, 2024, the International Agency for Research on Cancer (“IARC”) announced that they were convening a panel of scientists to re-evaluate the carcinogenicity of automotive gasoline (as well as some oxygenated additives). This panel would meet in Lyon, France, from February 25 to March 4, 2025.

So why were they doing this? In 1988, IARC previously classified gasoline as a Class 2B carcinogen (possibly carcinogenic to humans), meaning there was some evidence that it can cause cancer in humans, but the evidence was far from conclusive. Were there new, groundbreaking studies since then that warranted this updated review? Unfortunately, IARC was not transparent in the reasons behind this review.

Cynics looking at this announcement believed that, as an organization that has become increasingly more political and a haven for plaintiff’s experts, IARC had already made up their mind that they were going to conclude that gasoline was going to be bumped up to Class 1 known human carcinogen status. Waiting a year before the formal announcement was just window dressing to give their review an air of credibility. After all, the epidemiological studies concerning gasoline exposure were

consistent that exposure to gasoline does not increase the risk of cancer.

Supporters of IARC insisted a thorough review of the scientific evidence would be conducted and any new findings would reflect such a methodology.

On March 21, 2025, the working group of 20 scientists revealed their findings in *The Lancet Oncology*.¹ The cynics’ fears were verified. IARC did indeed re-classify gasoline as a Class 1 known human carcinogen, causing specifically acute myelogenous leukemia (“AML”) and bladder cancer. This determination contradicts the findings of various governmental agencies including the Environmental Protection Agency.²

What was the basis of this conclusion? IARC claims to have examined studies involving both humans and experimental animals, as well as underlying mechanistic evidence. As for human data, IARC notes that it reviewed occupational epidemiology studies involving service station attendants and gasoline distribution workers that assessed gasoline exposure and found them supportive of their conclusions. What is troubling about their purported reliance is that the papers cited in their *Lancet* article do not support such a conclusion. For example, in support of a causal connection between gasoline and

¹ Turner MC, Godderis L, Guénel P, Hopf N, Quintanilla-Vega B, Soares-Lima SC, et al. Carcinogenicity of automotive gasoline and some oxygenated gasoline additives, *Lancet Oncol*. Published online 21 March 2025.

² U.S. EPA. Evaluation of the Carcinogenicity of Unleaded Gasoline. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/6-87/001.

AML, they cite a 2007 mortality study involving thousands of refinery and petroleum workers.³ The conclusion section however states: “The only findings that showed clear evidence of an occupational cancer hazard were those for mesothelioma in oil refinery workers.” Moreover, the underlying data indicated that there was “no clear-cut excess of AML (or the slightly larger grouping of ANLL)” Nowhere in this paper do they claim that gasoline or working in or around gasoline causes AML.

How IARC could rely on this to support their conclusion is unknown. It is possible that IARC is not following traditional notions of statistical significance for standard mortality rates (“SMR”) or 95% confidence intervals. To do this though would be an abandonment of common scientific principles that are generally used in analyzing such studies.

The lack of a causal connection found in this 2007 paper is consistent with other large-scale studies looking at refinery workers, including those involved in transporting or distribution.⁴

Studies involving service station or mechanics also consistently show that they are not at an increased risk of AML.⁵ Therefore, it is unknown what studies upon which IARC is relying for the claims that these studies support their findings.

It is also important to note that they found that there was only “limited” evidence that gasoline causes myelodysplastic syndrome (“MDS”). Such a finding contradicts their position that they found mechanistic data sufficient to show that gasoline causes AML.

There is no dispute that MDS and AML are similar hematological diseases along the same continuum. As a result, treatment options are also similar for MDS and AML patients (e.g., chemotherapy, stem cell transplant, etc.). A normal blast cell count in humans is 5% or less. When a blast cell count is within the 5% to 20% range, this is indicative of MDS. AML is generally defined as a 20% or greater blast cell count in the bone marrow. It is this reason that it is common for MDS to progress to AML, a fact IARC concedes. If gasoline does indeed cause AML, then mechanistically, they should have

³ Sorahan T. Mortality of UK oil refinery and petroleum distribution workers, 1951–2003. *Occup Med* 2007; 57: 177–85.

⁴ O. Wong, L. Trent, F. Harris, Nested case-control study of leukemia, multiple myeloma, and kidney cancer in a cohort of petroleum workers exposed to gasoline, *Occup Environ Med*, 56 (1999) 217-221; O. Wong, F. Harris, T.J. Smith, Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States, *Environ. Health Perspect*, 101 Suppl 6 (1993) 63-76.

⁵ D.P. Loomis, D.A. Savitz, Occupation and leukemia mortality among men in 16 states: 1985-1987, *Am. J. Ind. Med*, 19 (1991) 509-521; J.N. Poynter, M.

Richardson, M. Roesler, C.K. Blair, B. Hirsch, P. Nguyen, A. Cioc, J.R. Cerhan, E. Warlick, Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study, *Int J Cancer*, 140 (2017) 23-33; C.F. Robinson, J.T. Walker, M.H. Sweeney, R. Shen, G.M. Calvert, P.K. Schumacher, J. Ju, S. Nowlin, Overview of the National Occupational Mortality Surveillance (NOMS) system: leukemia and acute myocardial infarction risk by industry and occupation in 30 US states 1985-1999, 2003-2004, and 2007, *Am. J. Ind. Med*, 58 (2015) 123-137.

similar findings for MDS, which they did not find.

The methodology IARC employed to determine gasoline causes bladder also appears flawed, and their apparent dismissal of smoking as a confounding factor (i.e. a variable that may mask an actual association or influence both the supposed cause and effect). Smoking is not just a confounding factor but *the confounding factor* that would influence the results of a bladder cancer analysis.

Cigarette smoking causes approximately 50% of all bladder cancers in the U.S.⁶ Persons who smoke are at a fourfold excess risk of developing bladder cancer. Therefore, it can be assumed that cigarette smoke is responsible for at least half of the bladder cancers being examined in any study.

IARC attempts to argue that any “[c]oncerns about confounding by smoking or engine exhausts were allayed because lung cancer incidence or mortality was generally not elevated in the available studies.” This reasoning dismissed smoking as a confounding factor because the persons in the studies they relied on did not have both lung and bladder cancer. The incidence of persons in the U.S. that have both lung and bladder cancers are rare, and there are no well-defined statistics as to how many of these persons exist. In addition, it is likely that the studies they relied upon failed to determine if these same populations had

other non-cancerous smoking related diseases such COPD, emphysema and coronary heart disease. Thus, if a person had both bladder cancer and COPD (of which the number one cause is smoking), it is likely their bladder disease is smoking related. If you flip the use of this methodology on its head and state that you can only prove that smoking causes bladder cancer if you also determine they did not also have lung cancer, that will of course likely lead to an erroneous conclusion.

While there have been a few nuclear verdicts involving alleged gasoline exposure, the plaintiff’s bar has, for the most part, not filed these types of cases in mass quantities. Historically, this was primarily due to the fact that general causation was difficult to prove. However, now armed with IARC’s new classification, we are likely to see not only more cases concerning persons who are exposed to gasoline in an occupational setting but potentially consumer-based lawsuits from individuals who simply fueled their vehicles.

The formal monograph will provide more specific detail as to all the studies IARC reviewed in support of its finding. Such monographs are likely not to be published until the later part of 2025 or early part of 2026. Given what information they provided to date in their recent disclosure, we would bet on the cynics who say that any insight into their underlying methodology will raise more questions than answer.

⁶ <https://www.nih.gov/news-events/nih-research-matters/smoking-bladder-cancer>

Past Committee Newsletters

Visit the Committee's newsletter archive online at www.iadclaw.org to read other articles published by the Committee. Prior articles include:

FEBRUARY 2025

[The Dust Settles on Causation: Tippin Decision is a Big Win for Talc Defendants](#)

Elizabeth M. Sorenson Brotten and Michael E. Tuttle

JANUARY 2025

[The European Union is Tackling Its Air Quality](#)

Sylvie Gallage-Alwis and Anélia Naydenova

JULY 2024

[PFAS Ban: France is Showing the Way to the European Union](#)

Sylvie Gallage-Alwis and Elias Boukachabine

JUNE 2024

[California Appellate Court Finds Principle Limiting Duty to Prevent Bystander Exposure to Worker's Household Members Does Not Apply to Strict Liability Claims](#)

Michael L. Fox and Katrina Garry

MAY 2024

[The Heat is On! How is the EU Regulation Wave Going to Shape Litigation Within and Outside Europe?](#)

Mark Clark, Peter Wende, and Döne Yalcin

JANUARY 2024

[What is the Role of Science in Determining a Causal Link? The Example of Pesticides in French Litigation](#)

Sylvie Gallage-Alwis and Elias Boukachabine

OCTOBER 2023

[Holding the Gate Against Talc Plaintiffs' Experts: New Jersey Appellate Court Reverses Multi-Hundred-Million Dollar Verdict](#)

Paul V. Majkowski and Lauren E. Russo

SEPTEMBER 2023

[California Supreme Court Finds Employers Have No Liability for Take-Home Exposure to COVID](#)

Michael L. Fox and Anshul Agrawal

MAY 2023

[The PFAS-Concern is Reaching the EU](#)

Sylvie Gallage-Alwis and Elias Boukachabine

FEBRUARY 2023

[Air Pollution in Europe: France, Condemned to be Sentenced?](#)

Sylvie Gallage-Alwis and Jordan Leblanc

SEPTEMBER 2022

[California Appellate Court Permits Defense Expert Testimony Regarding Causation to Meet Lower Standard When Offered to Challenge Plaintiff's Causation Evidence](#)

Michael L. Fox and Audrey M. Adams

APRIL 2022

[New Jersey Bankruptcy Court Rules that Johnson & Johnson's Texas Two-Step was not a Bad Faith Filing](#)

Stephanie A. Fox and Timothy Coughlan